# Nuwacell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuwacell

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.nuwacell.com
- Total disclosed funding: $33M
- Latest round: Series B (Nov 8, 2024)
- Investors on record: 11

## About

Established in 2016 and based in Hefei, China, Nuwacell operates as a biotech company focusing on iPSC technology research and clinical transformation services. It has a branch in Guangzhou. The founder and CSO of the company, Junying Yu graduated from the University of Pennsylvania. The co-founder and CTO of the company, Yin Zhang graduated from the Cornell University. In 2017, the GMP cell laboratory was officially put into operation. In November 2024, it raised CNY 235 million in series B funding led by new investor Guangzhou Kechuang Guofa Industry Fund Management. In February 2025, the company closed a venture funding from new investor Sfund.

The company specializes in biotechnological solutions, focusing primarily on developing innovative drug pipelines across various therapeutic areas. Their core product offerings include the Universal iDAP and Universal Islet therapies, which enhance tissue regeneration and immune response in cancer treatment. These product indications include inflammation repair and tumour immunity for patients with complex diseases. The company's target customer base includes hospitals, research organizations, and pharmaceutical companies.

The revenue model of the company is primarily built on B2B transactions with healthcare providers and research organizations. It generates revenue by providing innovative drug pipelines across various therapeutic areas. 

The company will use the series B funding to accelerate the development of its multiple clinical pipelines in the field of iPSC-derived cell therapy and the commercialization of subsequent products.

## Funding rounds

- Series B, Nov 8, 2024, $33M — Legend Capital, Guangzhou Financial Innovation Investment Holdings, Hefei State-Owned Assets Holding, Hefei High-tech Venture Capital, Guangzhou Guoju Venture Capital, Guangzhou Industry Investment Holding Group, Lotus Capital, In-sources Fund, Guangzhou Pharmaceutical Capital
- Series A, Sep 13, 2022 — Legend Capital, GF Xinde Investment, China Merchants Health Industry Holdings

## Investors

- Legend Capital — Series A, Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- China Merchants Health Industry Holdings — Series A
- Guangzhou Financial Innovation Investment Holdings (https://capitalatlas.ai/funds/guangzhou-financial-innovation-investment-holdings) — Series B
- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series B
- Hefei High-tech Venture Capital (https://capitalatlas.ai/funds/hefei-high-tech-venture-capital) — Series B
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series B
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series B
- Lotus Capital — Series B
- In-sources Fund (https://capitalatlas.ai/funds/in-sources-fund) — Series B
- Guangzhou Pharmaceutical Capital — Series B